Total Payments
$184,143
2024 Payments
$35,463
Companies
28
Transactions
143
Medicare Patients
2,482
Medicare Billing
$322,369
Payment Breakdown by Category
Consulting$151,874 (82.5%)
Travel$14,312 (7.8%)
Other$12,500 (6.8%)
Research$4,290 (2.3%)
Food & Beverage$1,151 (0.6%)
Gifts$16.12 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $151,874 | 80 | 82.5% |
| Travel and Lodging | $14,312 | 14 | 7.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,650 | 4 | 3.6% |
| Honoraria | $5,850 | 6 | 3.2% |
| Unspecified | $4,290 | 4 | 2.3% |
| Food and Beverage | $1,151 | 34 | 0.6% |
| Gift | $16.12 | 1 | 0.0% |
Payments by Type
General
$179,853
139 transactions
Research
$4,290
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Kala Pharmaceuticals, Inc. | $55,482 | 34 | $0 (2022) |
| Shire North American Group Inc | $26,772 | 31 | $0 (2019) |
| Dompe US, Inc. | $22,410 | 13 | $0 (2024) |
| Alcon Research LLC | $20,477 | 7 | $0 (2024) |
| Allergan, Inc. | $8,357 | 7 | $0 (2021) |
| Regeneron Pharmaceuticals, Inc. | $7,440 | 1 | $0 (2020) |
| Kowa Research Institute, Inc. | $7,000 | 12 | $0 (2023) |
| ABBVIE INC. | $6,825 | 2 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $6,629 | 3 | $0 (2024) |
| Bausch & Lomb Americas Inc. | $5,000 | 2 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $35,463 | 20 | Alcon Research LLC ($19,500) |
| 2023 | $9,052 | 7 | Dompe US, Inc. ($5,550) |
| 2022 | $17,991 | 12 | Kala Pharmaceuticals, Inc. ($6,134) |
| 2021 | $25,503 | 21 | Kala Pharmaceuticals, Inc. ($8,060) |
| 2020 | $55,281 | 29 | Kala Pharmaceuticals, Inc. ($37,500) |
| 2019 | $8,625 | 11 | Kala Pharmaceuticals, Inc. ($3,788) |
| 2018 | $2,232 | 6 | Carl Zeiss Meditec, Inc. ($2,000) |
| 2017 | $29,996 | 37 | Shire North American Group Inc ($24,955) |
All Payment Transactions
143 individual payment records from CMS Open Payments — Page 6 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/15/2017 | Shire North American Group Inc | XIIDRA (Drug) | Food and Beverage | In-kind items and services | $23.89 | General |
| Category: OPTHALMICS | ||||||
| 09/10/2017 | Shire North American Group Inc | XIIDRA (Drug) | Travel and Lodging | In-kind items and services | $6,010.06 | General |
| Category: OPTHALMICS | ||||||
| 09/10/2017 | Shire North American Group Inc | XIIDRA (Drug) | Travel and Lodging | In-kind items and services | $413.52 | General |
| Category: OPTHALMICS | ||||||
| 08/03/2017 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 07/21/2017 | Carl Zeiss Meditec, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 07/03/2017 | Theravance Biopharma Inc. | — | Consulting Fee | Cash or cash equivalent | $530.00 | General |
| 06/30/2017 | Shire North American Group Inc | XIIDRA (Drug) | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| Category: OPTHALMICS | ||||||
| 06/30/2017 | Shire North American Group Inc | XIIDRA (Drug) | Food and Beverage | In-kind items and services | $10.15 | General |
| Category: OPTHALMICS | ||||||
| 06/17/2017 | Shire North American Group Inc | XIIDRA (Drug) | Travel and Lodging | In-kind items and services | $179.18 | General |
| Category: OPTHALMICS | ||||||
| 06/16/2017 | Carl Zeiss Meditec, Inc. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 06/16/2017 | Shire North American Group Inc | XIIDRA (Drug) | Travel and Lodging | In-kind items and services | $158.42 | General |
| Category: OPTHALMICS | ||||||
| 06/08/2017 | Shire North American Group Inc | XIIDRA (Drug) | Travel and Lodging | In-kind items and services | $375.96 | General |
| Category: OPTHALMICS | ||||||
| 05/25/2017 | NovaBay Pharmaceuticals, Inc. | Avenova (Device) | Food and Beverage | Cash or cash equivalent | $16.99 | General |
| Category: Ophthalmology | ||||||
| 03/01/2017 | Allergan Inc. | RESTASIS (Drug) | Food and Beverage | In-kind items and services | $10.81 | General |
| Category: DRY EYE | ||||||
| 02/15/2017 | Allergan Inc. | RESTASIS (Drug) | Food and Beverage | In-kind items and services | $21.89 | General |
| Category: DRY EYE | ||||||
| 01/24/2017 | Mallinckrodt LLC | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $17.47 | General |
| Category: AUTOIMMUNE AND RARE DISEASE | ||||||
| 01/23/2017 | Shire North American Group Inc | XIIDRA (Drug) | Food and Beverage | In-kind items and services | $5.32 | General |
| Category: OPTHALMICS | ||||||
| 01/13/2017 | Carl Zeiss Meditec, Inc. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Goblet Cell Degranulation Produced by Nasal Neurostimulation A Randomized, Controlled Study in Patients with Dry Eye Disease | Allergan Inc. | $2,215 | 1 |
| BAWH_KSI | KOWA COMPANY, LTD. | $1,750 | 2 |
| GOBLET CELL DEGRANULATION PRODUCED BY NASAL NEUROSTIMULATION: A RANDOMIZED, CONTROLLED STUDY IN PATIENTS WITH DRY EYE DISEASE | Allergan, Inc. | $325.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 605 | 836 | $383,898 | $79,954 |
| 2022 | 14 | 650 | 865 | $408,958 | $85,161 |
| 2021 | 11 | 616 | 829 | $357,044 | $81,946 |
| 2020 | 11 | 611 | 840 | $346,133 | $75,307 |
Total Patients
2,482
Total Services
3,370
Medicare Billing
$322,369
Procedure Codes
48
All Medicare Procedures & Services
48 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 92014 | Established patient complete exam of visual system | Office | 2023 | 232 | 239 | $83,172 | $21,302 | 25.6% |
| 66984 | Removal of cataract with insertion of prosthetic lens | Office | 2023 | 29 | 44 | $119,108 | $19,214 | 16.1% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 137 | 293 | $72,664 | $19,096 | 26.3% |
| 66821 | Removal of recurring cataract in lens capsule using a laser | Office | 2023 | 17 | 21 | $35,091 | $5,346 | 15.2% |
| 68115 | Removal of growth of eyelid lining, more than 1.0 cm | Office | 2023 | 13 | 14 | $29,348 | $4,504 | 15.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 31 | 31 | $14,291 | $3,997 | 28.0% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 32 | 32 | $13,184 | $3,197 | 24.2% |
| 92136 | Measurement of corneal curvature and depth of eye | Office | 2023 | 25 | 56 | $6,189 | $1,620 | 26.2% |
| 92134 | Imaging of retina | Office | 2023 | 15 | 16 | $1,792 | $471.29 | 26.3% |
| 68841 | Insertion of drug delivery implant into tear duct of eye | Office | 2023 | 24 | 34 | $5,542 | $451.52 | 8.1% |
| 83516 | Analysis of substance using immunoassay technique, multiple step method | Office | 2023 | 39 | 39 | $1,794 | $440.70 | 24.6% |
| 76519 | Ultrasound scan to determine eye length and lens power | Office | 2023 | 11 | 17 | $1,723 | $315.63 | 18.3% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 271 | 283 | $99,899 | $24,863 | 24.9% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 136 | 304 | $75,696 | $19,830 | 26.2% |
| 66984 | Removal of cataract with insertion of prosthetic lens | Office | 2022 | 33 | 42 | $113,946 | $18,137 | 15.9% |
| 66821 | Removal of recurring cataract in lens capsule using a laser | Office | 2022 | 22 | 27 | $45,414 | $6,774 | 14.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 32 | 32 | $14,848 | $4,309 | 29.0% |
| 68115 | Removal of growth of eyelid lining, more than 1.0 cm | Office | 2022 | 12 | 12 | $23,469 | $3,881 | 16.5% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 29 | 29 | $12,122 | $2,520 | 20.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 12 | 12 | $6,024 | $1,649 | 27.4% |
| 76519 | Ultrasound scan to determine eye length and lens power | Office | 2022 | 22 | 29 | $3,801 | $846.32 | 22.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 13 | 13 | $3,289 | $798.63 | 24.3% |
| 92134 | Imaging of retina | Office | 2022 | 13 | 13 | $1,482 | $439.66 | 29.7% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 14 | 14 | $2,842 | $428.48 | 15.1% |
| 68841 | Insertion of drug delivery implant into tear duct of eye | Office | 2022 | 25 | 31 | $5,022 | $415.87 | 8.3% |
About Dr. Stephen Pflugfelder, M.D
Dr. Stephen Pflugfelder, M.D is a Ophthalmology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/18/2005. The National Provider Identifier (NPI) number assigned to this provider is 1851380216.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephen Pflugfelder, M.D has received a total of $184,143 in payments from pharmaceutical and medical device companies, with $35,463 received in 2024. These payments were reported across 143 transactions from 28 companies. The most common payment nature is "Consulting Fee" ($151,874).
As a Medicare-enrolled provider, Pflugfelder has provided services to 2,482 Medicare beneficiaries, totaling 3,370 services with total Medicare billing of $322,369. Data is available for 4 years (2020–2023), covering 48 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Houston, TX
- Active Since 10/18/2005
- Last Updated 11/27/2020
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1851380216
Products in Payments
- EYSUVIS (Drug) $35,890
- XIIDRA (Drug) $25,022
- INVELTYS (Drug) $15,227
- DUPIXENT (Biological) $7,440
- ACTHAR (Biological) $6,647
- LOTEMAX (Drug) $5,000
- Oxervate (Drug) $2,850
- PROVENGE (Drug) $1,500
- OXERVATE (Drug) $115.36
- Whitestart Phacoemulsficiation System (Device) $68.54
- Cequa (Drug) $35.27
- RESTASIS (Drug) $32.70
- CLARUS (Device) $25.45
- Avenova (Device) $16.99
- None Specified (Medical Supply) $16.12
- TEARCARE SYSTEM (Device) $13.93
- Prokera (Device) $11.66
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Houston
Stephen Slade, M.d, M.D
Ophthalmology — Payments: $1.5M
Ophthalmology $1.5M
Dr. Christina Weng, M.d., M.b.a, M.D., M.B.A
Ophthalmology — Payments: $635,330
Ophthalmology $635,330
Zaina Al-Mohtaseb, Md, MD
Ophthalmology — Payments: $559,665
Ophthalmology $559,665
Dr. John Micheletti, M.d, M.D
Ophthalmology — Payments: $555,738
Ophthalmology $555,738
David Brown, M.d, M.D
Ophthalmology — Payments: $488,095
Ophthalmology $488,095
Dr. Douglas Koch, M.d, M.D
Ophthalmology — Payments: $457,260
Ophthalmology $457,260